[go: up one dir, main page]

CL2020000462A1 - Compuestos espirocíclicos y sus métodos de preparación y uso. - Google Patents

Compuestos espirocíclicos y sus métodos de preparación y uso.

Info

Publication number
CL2020000462A1
CL2020000462A1 CL2020000462A CL2020000462A CL2020000462A1 CL 2020000462 A1 CL2020000462 A1 CL 2020000462A1 CL 2020000462 A CL2020000462 A CL 2020000462A CL 2020000462 A CL2020000462 A CL 2020000462A CL 2020000462 A1 CL2020000462 A1 CL 2020000462A1
Authority
CL
Chile
Prior art keywords
preparation
methods
spirocyclic compounds
compositions
compounds
Prior art date
Application number
CL2020000462A
Other languages
English (en)
Inventor
Olivia D Weber
Cheryl A Grice
Daniel J Buzard
Michael B Shaghafi
Todd K Jones
Original Assignee
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck La Jolla Research Center Inc filed Critical Lundbeck La Jolla Research Center Inc
Publication of CL2020000462A1 publication Critical patent/CL2020000462A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

EN LA PRESENTE SE PROPORCIONAN COMPUESTOS Y COMPOSICIONES ÚTILES COMO MODULADORES DE MAGL. ADEMÁS, LOS COMPUESTOS Y LAS COMPOSICIONES EN CUESTIÓN SON ÚTILES PARA EL TRATAMIENTO DEL DOLOR.
CL2020000462A 2017-08-29 2020-02-25 Compuestos espirocíclicos y sus métodos de preparación y uso. CL2020000462A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762551721P 2017-08-29 2017-08-29

Publications (1)

Publication Number Publication Date
CL2020000462A1 true CL2020000462A1 (es) 2020-07-10

Family

ID=65527860

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000462A CL2020000462A1 (es) 2017-08-29 2020-02-25 Compuestos espirocíclicos y sus métodos de preparación y uso.

Country Status (27)

Country Link
US (1) US11142526B2 (es)
EP (1) EP3675847B1 (es)
JP (1) JP7257387B2 (es)
KR (1) KR20200046061A (es)
CN (1) CN111050765B (es)
AU (1) AU2018323459A1 (es)
BR (1) BR112020004101A2 (es)
CA (1) CA3072923A1 (es)
CL (1) CL2020000462A1 (es)
CO (1) CO2020001724A2 (es)
CR (1) CR20200089A (es)
DO (1) DOP2020000039A (es)
EA (1) EA202090312A1 (es)
EC (1) ECSP20013337A (es)
ES (1) ES2952332T3 (es)
GE (2) GEP20217327B (es)
IL (1) IL272580B (es)
JO (1) JOP20200023A1 (es)
MA (1) MA50041A (es)
MX (1) MX2020002251A (es)
NI (1) NI202000014A (es)
PE (1) PE20200664A1 (es)
PH (1) PH12020500372A1 (es)
SG (1) SG11202001022TA (es)
UA (1) UA126685C2 (es)
WO (1) WO2019046318A1 (es)
ZA (1) ZA202001208B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028085B1 (ru) 2012-01-06 2017-10-31 Эбайд Терапьютикс, Инк. Карбаматные соединения и их применение
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
AU2018323459A1 (en) 2017-08-29 2020-02-20 H. Lundbeck A/S. Spirocycle compounds and methods of making and using same
EP3675848B1 (en) 2017-08-29 2022-03-23 H. Lundbeck A/S Spirocycle compounds and methods of making and using same
CN114096545A (zh) * 2019-07-09 2022-02-25 豪夫迈·罗氏有限公司 新杂环化合物
CN116096723A (zh) * 2020-08-26 2023-05-09 豪夫迈·罗氏有限公司 用作magl抑制剂的杂环化合物
UY39516A (es) * 2020-11-13 2022-05-31 H Lundbeck As Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
WO2023130023A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
CN119137114A (zh) 2022-05-04 2024-12-13 H.隆德贝克有限公司 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03008109A (es) 2001-03-07 2003-12-12 Pfizer Prod Inc Moduladores de la actividad de receptores de quimiocinas.
EP2065369A4 (en) 2006-08-23 2011-12-28 Astellas Pharma Inc UREA CONNECTION OR SALT THEREOF
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2011040905A1 (en) 2009-09-29 2011-04-07 Polyone Corporation Polyester articles having simulated metallic or pearlescent appearance
PT2491038T (pt) 2009-10-23 2016-07-14 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disubstituídos como modeladores de recetores de orexina
AU2011223898A1 (en) 2010-03-04 2012-09-13 Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
EA028085B1 (ru) * 2012-01-06 2017-10-31 Эбайд Терапьютикс, Инк. Карбаматные соединения и их применение
CN104684915B (zh) 2012-09-25 2017-10-31 霍夫曼-拉罗奇有限公司 新型双环衍生物
CA2917050A1 (en) 2013-07-03 2015-01-08 Todd K. Jones Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2015179559A2 (en) * 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
EP3271352B1 (en) 2015-03-18 2021-05-12 H. Lundbeck A/S Piperazine carbamates and methods of making and using same
TN2017000544A1 (en) 2015-07-31 2019-04-12 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
EP3436444B1 (en) 2016-03-31 2020-05-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
RS65016B1 (sr) 2016-11-16 2024-01-31 H Lundbeck As Kristalni oblik magl inhibitora
US11273159B2 (en) 2016-11-16 2022-03-15 H. Lundbeck A/S Pharmaceutical formulations
EP3675848B1 (en) 2017-08-29 2022-03-23 H. Lundbeck A/S Spirocycle compounds and methods of making and using same
AU2018323459A1 (en) 2017-08-29 2020-02-20 H. Lundbeck A/S. Spirocycle compounds and methods of making and using same

Also Published As

Publication number Publication date
EP3675847A1 (en) 2020-07-08
ZA202001208B (en) 2021-08-25
UA126685C2 (uk) 2023-01-11
EA202090312A1 (ru) 2020-08-05
KR20200046061A (ko) 2020-05-06
CR20200089A (es) 2020-04-08
WO2019046318A1 (en) 2019-03-07
MX2020002251A (es) 2020-07-20
NI202000014A (es) 2020-07-28
ECSP20013337A (es) 2020-04-22
CO2020001724A2 (es) 2020-02-28
RU2020107163A3 (es) 2022-03-15
EP3675847B1 (en) 2023-07-12
JP7257387B2 (ja) 2023-04-13
IL272580B (en) 2022-09-01
SG11202001022TA (en) 2020-03-30
EP3675847A4 (en) 2021-01-06
EP3675847C0 (en) 2023-07-12
IL272580A (en) 2020-03-31
US20200255427A1 (en) 2020-08-13
PE20200664A1 (es) 2020-06-11
BR112020004101A2 (pt) 2020-09-24
GEP20217327B (en) 2021-12-10
MA50041A (fr) 2020-07-08
CN111050765B (zh) 2024-01-02
DOP2020000039A (es) 2020-08-31
PH12020500372A1 (en) 2020-12-07
CN111050765A (zh) 2020-04-21
JOP20200023A1 (ar) 2020-02-02
US11142526B2 (en) 2021-10-12
RU2020107163A (ru) 2021-09-30
GEAP202115281A (en) 2021-08-10
AU2018323459A1 (en) 2020-02-20
CA3072923A1 (en) 2019-03-07
JP2020532545A (ja) 2020-11-12
ES2952332T3 (es) 2023-10-30

Similar Documents

Publication Publication Date Title
CL2020000463A1 (es) Compuestos espirocíclicos y sus métodos de preparación y uso.
CL2020000462A1 (es) Compuestos espirocíclicos y sus métodos de preparación y uso.
CO2019004945A2 (es) Inhibidores de la magl
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2019003398A1 (es) Inhibidores pirazólicos de magl.
NI202000080A (es) Inhibidores de magl
CL2019001339A1 (es) Inhibidores de la magl.
CL2016003056A1 (es) Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer.
CL2017003404A1 (es) Compuestos antibacterianos
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
CO2019005038A2 (es) Inhibidores de magl
MX377877B (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
CL2019003397A1 (es) Inhibidores pirazólicos de magl.
MX2018008644A (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espir o-[4.5]-decano.
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano